After years of regulatory paralysis, the federal government and a growing number of states are finally cracking down on kratom products sold at gas stations and convenience stores. On July 29, 2025, the FDA recommended that 7-hydroxymitragynine — a concentrated kratom derivative commonly found in gas station shots and capsules — be classified as a Schedule I controlled substance under the Controlled Substances Act. That recommendation, now under review by the DEA, marks the most aggressive federal move against kratom in the substance’s controversial history in the United States. Meanwhile, Utah’s legislature passed SB45 in March 2026 by a vote of 63 to 10 in the House and unanimously in the Senate, banning kratom sales in gas stations and convenience stores entirely. The bill’s sponsor, Sen.
Mike McKell, did not mince words, calling the products “gas station heroin.” For families navigating dementia care and brain health, the kratom issue is not abstract. Older adults managing chronic pain, sleep disruption, or anxiety — common companions to cognitive decline — may encounter these products at the gas station counter, marketed with vague promises of relief. Caregivers may find bottles in a loved one’s home without understanding what they contain or how they interact with existing medications. The regulatory landscape is shifting fast, and understanding what is happening, where, and why matters for anyone trying to protect a vulnerable person’s neurological health. This article covers the full scope of government action on gas station kratom: the FDA’s federal scheduling recommendation, state-level bans and regulations from Utah to Connecticut, safety and contamination concerns, and what the patchwork of new laws means in practical terms for consumers and caregivers.
Table of Contents
- Why Is the Government Finally Acting on Kratom Sold in Gas Stations?
- What Utah’s “Gas Station Heroin” Ban Means for Kratom Access
- How Kansas City and Local Governments Are Banning Gas Station Kratom
- Which States Have Banned or Restricted Kratom, and What Are the Tradeoffs?
- Kratom Safety Concerns That Dementia Caregivers Cannot Ignore
- How 7-OH Products Differ from Traditional Kratom Leaf
- What Comes Next for Kratom Regulation and What Caregivers Should Watch
- Conclusion
- Frequently Asked Questions
Why Is the Government Finally Acting on Kratom Sold in Gas Stations?
The short answer is scale and harm. The U.S. kratom market hit $2.56 billion in 2025, with projections to reach $7.79 billion by 2032 at a 17.2% compound annual growth rate. Roughly 73.53% of kratom sales occur through brick-and-mortar channels — gas stations, smoke shops, and convenience stores — meaning the vast majority of this multi-billion-dollar market operates in retail settings with little to no oversight on product quality, dosing, or consumer age. The concentrated liquid extract segment alone, the format most commonly found behind gas station counters, was valued at $218.3 million in 2025 and is projected to nearly double to $479.5 million by 2032. What changed the calculus for regulators was the emergence of 7-hydroxymitragynine, or 7-OH, as a commercially concentrated product. The FDA’s July 2025 announcement made a critical distinction: 7-OH exists only in trace amounts in natural kratom leaves, but commercial products sold in gas stations contain unnaturally high, often synthetically derived concentrations.
In other words, what consumers purchase off a gas station shelf bears little resemblance to the traditional plant. The agency issued warning letters to seven companies for illegally distributing 7-OH products, and the DEA is now reviewing the scheduling recommendation. A public comment period must occur before any final classification becomes law. The comparison to earlier regulatory failures is instructive. Synthetic cannabinoids — sold for years as “Spice” or “K2” in similar retail settings — went through a nearly identical trajectory: widespread availability, delayed federal action, and a patchwork of state laws before scheduling. Kratom derivatives appear to be following the same path, but with one difference. This time, states are not waiting for Washington.
What Utah’s “Gas Station Heroin” Ban Means for Kratom Access
Utah’s SB45, passed in early March 2026, is the most comprehensive state-level response to gas station kratom yet. The law bans kratom sales in gas stations and convenience stores outright. Only pure kratom leaf — not extracts, not concentrates, not 7-OH products — may be sold, and only in smoke shops, and only to adults 21 and older. Kratom manufacturers operating in Utah have one year to stop producing anything other than pure kratom leaf. Perhaps most significantly, SB45 repeals Utah’s 2019 Kratom Consumer Protection Act, which had been held up by the kratom industry as a model for reasonable regulation. The legislature evidently decided that framework was not working. However, there is a limitation worth noting. Utah’s ban targets the point of sale, not possession.
A person can still legally possess kratom in Utah — they simply cannot buy it at a gas station or convenience store. This means products purchased online or in other states can still enter the market informally. For caregivers monitoring a loved one’s substance use, the ban reduces casual access but does not eliminate it entirely. The online kratom market, which accounts for roughly a quarter of sales, remains unaffected by Utah’s law. The political dynamics are also telling. The bill passed with overwhelming bipartisan support — unanimous in the Senate and 63 to 10 in the House. That margin suggests the “gas station heroin” framing resonated across party lines in a state not typically associated with aggressive substance regulation. Whether other legislatures follow Utah’s lead or pursue different models will likely depend on local political conditions and how aggressively the kratom industry lobbies against similar bills.
How Kansas City and Local Governments Are Banning Gas Station Kratom
While state-level action gets the most attention, some of the most immediate changes are happening at the municipal level. On February 12, 2026, the Kansas City Council unanimously passed an ordinance banning synthetic kratom — specifically 7-OH products — and restricting natural kratom sales. Under the new rules, natural kratom can only be sold to adults 21 and older with a special city license. Products that can be smoked, vaped, or that look like candy are banned. Stores have 60 days to comply, and violations carry fines up to $1,000. Kansas City’s ordinance illustrates a pattern emerging across the country.
Local municipalities in Illinois and Mississippi are also moving to ban both the sale and possession of kratom, going further than most state laws by criminalizing consumers, not just sellers. This creates a confusing legal landscape where a product may be legal to buy in one town and a criminal offense to possess in the next county over. For families dealing with dementia care across multiple locations — say, an aging parent who splits time between a primary residence and a child’s home in another state — the inconsistency is a genuine practical problem. The Kansas City model is worth watching because it attempts a middle path: banning the most dangerous derivatives while allowing regulated access to natural kratom leaf. Whether that distinction holds up in practice depends on enforcement. Gas station operators are not pharmacists, and expecting them to verify the chemical composition of the products on their shelves is optimistic at best.
Which States Have Banned or Restricted Kratom, and What Are the Tradeoffs?
As of early 2026, eight states maintain full bans on kratom: Alabama, Arkansas, Connecticut, Indiana, Louisiana (effective August 2025), Rhode Island (ban in effect until a regulated framework begins April 2026), Vermont, and Wisconsin. Connecticut became the seventh state to classify kratom and all its derivatives, including 7-OH, as Schedule I controlled substances when Governor Ned Lamont signed the measure on June 25, 2025. Under Schedule I, no kratom products may be sold or possessed in the state. The tradeoff between prohibition and regulation is real. Full bans like Connecticut’s are simple to enforce but push users toward unregulated online markets or black-market sources with even less quality control. Rhode Island illustrates the alternative.
It became the first state to reverse a kratom ban entirely, signing a Kratom Consumer Protection Act in July 2025 that takes effect April 1, 2026. The new framework replaces prohibition with a regulated system requiring a 21-and-older age limit, labeling requirements, and a licensing system. The bet Rhode Island is making is that regulated access is safer than prohibition — a familiar argument from the cannabis debate, though the evidence base for kratom is considerably thinner. Washington State is exploring yet another approach. Lawmakers there are considering three separate bills to regulate kratom sold at convenience stores and smoke shops, including potential taxes on kratom products. Taxation as a regulatory mechanism has the advantage of generating revenue for enforcement and public health programs, but it also implicitly legitimizes a product whose safety profile remains disputed. For families concerned about brain health, the patchwork means that the protections available to a vulnerable person depend entirely on geography.
Kratom Safety Concerns That Dementia Caregivers Cannot Ignore
The safety data on kratom is incomplete, but what exists should give caregivers pause. The FDA issued its first-ever mandatory recall of kratom products — from Triangle Pharmanaturals LLC — due to Salmonella contamination after the company refused a voluntary recall. This is not a theoretical risk. Gas station kratom products are manufactured with minimal federal oversight, and contamination with bacteria, heavy metals, or undisclosed additives is a documented problem, not a hypothetical one. A Florida study covering 2020 through 2021 found 551 confirmed kratom exposures. Of those, 484 — or 87.8% — died from drug intoxication. That number demands context: 93% of those deaths involved polysubstance use, meaning the vast majority of fatal cases combined kratom with other drugs.
Only 6.5% involved kratom alone. This does not make kratom safe, but it does mean the risk profile changes dramatically depending on what else a person is taking. For older adults on multiple medications — blood thinners, antidepressants, sedatives, or dementia drugs like memantine or donepezil — the interaction risks are largely unstudied and poorly understood. From 2011 to 2017, 1,807 kratom exposures were reported to U.S. poison control centers, with 65% of those reports occurring in 2016 and 2017 alone, reflecting the product’s rapid growth in retail availability. The upward trend in exposures tracks directly with the expansion of gas station sales. For caregivers, the practical warning is this: if a loved one with cognitive decline has access to gas station kratom, the risk is not just the kratom itself but the near-certainty that it will interact unpredictably with existing medications, and the strong likelihood that the person may not remember or report having taken it.
How 7-OH Products Differ from Traditional Kratom Leaf
The distinction between traditional kratom leaf and 7-hydroxymitragynine products is not a technicality — it is the crux of the entire regulatory debate. Traditional kratom leaf contains two primary alkaloids, mitragynine and 7-hydroxymitragynine, with 7-OH present in only trace amounts. The concentrated products sold at gas stations, however, contain synthetically boosted levels of 7-OH that are many times higher than anything found in nature. The FDA has been explicit on this point: these are not herbal supplements in any meaningful sense.
They are concentrated opioid-receptor agonists packaged in colorful bottles next to the energy drinks and beef jerky. This matters for brain health in a specific way. Opioid-receptor activity affects cognition, memory consolidation, and neuroinflammation — all processes already compromised in someone with dementia or mild cognitive impairment. A person reaching for a gas station kratom shot for pain relief or mood elevation may be unknowingly accelerating the very cognitive decline their family is trying to manage. The fact that these products are sold without dosing guidance, interaction warnings, or age verification in many jurisdictions makes the situation worse.
What Comes Next for Kratom Regulation and What Caregivers Should Watch
The next twelve months will likely determine whether the United States ends up with a coherent national framework for kratom or a permanent patchwork of conflicting state and local laws. The DEA’s response to the FDA’s scheduling recommendation for 7-OH is the single most consequential pending decision. If 7-OH is classified as Schedule I at the federal level, it would effectively remove the most dangerous gas station products from the market nationwide, regardless of what individual states do. However, the required public comment period and review process means this will not happen overnight. The kratom industry, which generated over $2.5 billion in 2025, will lobby aggressively against scheduling.
For dementia caregivers and families focused on brain health, the practical advice is straightforward. Do not wait for the law to catch up. Talk to your loved one’s physician about kratom specifically — most doctors will not raise the subject unprompted because they do not think to ask about gas station supplements. Check medicine cabinets and kitchen counters for small bottles with names that reference “extract,” “7-OH,” or “enhanced.” If you find them, do not panic, but do bring them to the next medical appointment. The regulatory environment is moving in the direction of restriction, but it has not arrived yet, and the products are still on shelves in most of the country.
Conclusion
The government’s response to gas station kratom is finally materializing after years of inaction. The FDA’s recommendation to schedule 7-OH as a controlled substance, Utah’s sweeping ban on gas station sales, Kansas City’s municipal ordinance, Connecticut’s Schedule I classification, and Rhode Island’s regulated-access experiment all signal that the era of unregulated kratom at the checkout counter is ending. But the transition is messy, inconsistent, and slow. Eight states have full bans, others are regulating, and most have done nothing at all.
Federal action through the DEA could bring uniformity, but the timeline remains uncertain. For anyone involved in dementia care or brain health, the message from this regulatory shift is not simply about one plant or its derivatives. It is about the broader problem of unregulated psychoactive substances being sold in the most accessible retail environments imaginable, to consumers who may have no idea what they are buying or how it interacts with their existing medications and conditions. The laws are changing. In the meantime, the responsibility falls on caregivers, families, and healthcare providers to fill the gap that regulation has not yet closed.
Frequently Asked Questions
Is kratom legal in my state?
It depends. As of early 2026, eight states fully ban kratom: Alabama, Arkansas, Connecticut, Indiana, Louisiana, Rhode Island (until April 2026 when regulation begins), Vermont, and Wisconsin. Many other states and cities are considering restrictions. Check your state and local laws, as the situation is changing rapidly.
What is 7-hydroxymitragynine and why is it different from regular kratom?
7-hydroxymitragynine, or 7-OH, is a compound found in trace amounts in natural kratom leaf. The products sold in gas stations contain synthetically concentrated levels far exceeding what occurs naturally. The FDA has recommended classifying 7-OH as a Schedule I substance because of its potent opioid-like effects.
Can kratom interact with dementia medications?
Kratom’s interactions with common dementia medications like donepezil, memantine, or antidepressants are not well studied, which is itself cause for concern. Kratom acts on opioid receptors and may affect cognition, sedation, and liver metabolism of other drugs. Always consult a physician before combining kratom with any prescription medication.
Are gas station kratom products tested for contaminants?
In most states, no. There is no federal requirement for third-party testing of kratom products. The FDA’s first mandatory kratom recall — for Salmonella contamination — occurred only after a company refused to recall voluntarily. Product quality and safety vary enormously, especially in gas station and convenience store settings.
What should I do if I find kratom products in a family member’s home?
Do not dispose of them without a conversation. Bring the products to the person’s next medical appointment so their doctor can evaluate potential interactions with existing medications. If the person has cognitive impairment, inform all members of the care team so they can monitor for side effects or changes in behavior.
